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Genetics of autoimmune diseases represent a growing domain with surpassing biomarker results
with rapid progress. The exact cause of Rheumatoid Arthritis (RA) is unknown, but it is
thought to have both a genetic and an environmental bases. Genetic biomarkers are capable
of changing the supervision of RA by allowing not only the detection of susceptible individuals,
but also early diagnosis, evaluation of disease severity, selection of therapy, and monitoring of
response to therapy. This review is concerned with not only the genetic biomarkers of RA but
also the methods of identifying them. Many of the identiﬁed genetic biomarkers of RA were
identiﬁed in populations of European and Asian ancestries. The study of additional human
populations may yield novel results. Most of the researchers in the ﬁeld of identifying RA
biomarkers use single nucleotide polymorphism (SNP) approaches to express the signiﬁcance
of their results. Although, haplotype block methods are expected to play a complementary role
in the future of that ﬁeld.
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Introduction
RA is an autoimmune disease that causes chronic inﬂamma-
tion of the joints and other areas of the body. RA is character-
ized by periods of disease development and attenuation. RA
tends to affect multiple joints usually, but not always, in sym-
metrical patterns [1].
The US and UK populations are affected by RA disease
with 1% approximately. In some other ethnicities, such as Chi-
na, Japan and some black populations in rural South Africa,
assessment of the spread of the disease is as low as 0.2–
0.3%. The affected women are approximately twice the affect-
ed men. It most often starts within the range of 45–55 years of
age [2].
The precise etiology of RA has not been established yet.
The cause of RA is a very active area of the worldwide
research. It is believed that the tendency to develop RA may
be genetically inherited. Also, environmental factors, such as
smoking tobacco, may cause the malfunction of the immune
system in susceptible individuals [3].
There is no singular test for diagnosing RA. Instead, RA
diagnosis is based on a combination of (1) the presentation
of the joints involved, (2) the characteristic joint stiffness in
the morning, (3) positive rheumatoid factor (RF) and citrulline
antibody, and (4) the ﬁndings of rheumatoid nodules and
radiographic changes. There is no known speciﬁc cure for
RA. To date, the goal of treatment in RA is to (a) reduce joint
inﬂammation and pain, (b) maximize joint function, and (c)
Fig. 1 More than 35 risk loci that have been previously
identiﬁed as biomarkers for RA disease [10].
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tomized according to many factors such as disease activity,
types of joints involved, general health, age, and patient’s
occupation.
The ﬁrst-line of drug treatment, such as cortisone, is used to
reduce pain and inﬂammation in RA patients. The disease-
modifying anti-rheumatic drugs (DMARDs), such as
methotrexate, promote disease remission and prevent progres-
sive joint destruction. In some cases with severe joint deformi-
ty, surgery may be necessary [4].
Biological drugs which are considered other kinds of
DMARDs, offer more speciﬁc action and provide clues to
other biological pathways and biomarkers. They work on the
immune system and block signals that lead to inﬂammation.
For example, (etanercept, inﬂiximab, and adalimumab) block
tumor necrosis factor alpha (TNFa) which is an important
player in RA. A test, predicting the response to anti-TNFa
treatment, would be an important tool to rheumatologists.
This test will reduce the deterioration of the patient and save
time and money by deﬁning the most effective biological drug
before its usage [5].
Due to the extremely increase in the diseases, re-charac-
terization of disease in pathological and physiological terms
using biomarkers is a turn to the future of medicine. A
biomarker is deﬁned as any parameter that can be objectively
examined and measured as a marker of (a) normal biological
processes, (b) pathogenic processes, or (c) pharmacological
response to a therapeutic intervention. These indicators could
include a wide range of biochemical materials, such as nucleic
acids, proteins, sugars, lipids, and metabolites, as well as whole
cells or biophysical characteristics of tissues. Detection of
biomarkers, either individually or as larger sets or patterns,
can be accomplished by a wide variety of methods, ranging
from biochemical analysis of blood or tissue samples to biome-
dical imaging [6].
SNPs are considered as the most common type of sequence
variation in genomes. Most commonly, SNPs can serve as
valuable genetic biomarkers; guiding biologists in detecting
genes that are related to common diseases [7]. In this review,
the SNPs were used as biomarkers for detecting RA. The var-
iation in these nucleotides has higher frequency in affected
people than in normal individuals. Most of these nucleotides
are located within genes or near genes. Most of those genes
are involved in immune regulation. As RA is an autoimmune
disease, so those genes suggest an important set of processes
involved in RA pathogenesis [8].Genome-wide association studies (GWAS), using SNPs,
have marked a collection of genes that may be associated with
RA susceptibility, especially the genes that encode
immunoregulatory factors [9]. TNFa is a part of the
immunopathogenesis and an early stage biomarker for RA.
It is reasonable to assume that TNFa levels are elevated long
before the appearance of symptoms on the patient [5]. Fig. 1
shows a historical view of RA genetic biomarkers until 2010.
HLA (human leukocyte antigen)-DR4 and shared epitope
(SE) (multiple alleles at the HLA–DRB1 locus) represent
approximately 15% of RA disease risk factors. The last decade
reﬂects enormous growth in RA biomarker ﬁndings [10].
Haplotype block
Linkage Disequilibrium (LD) speciﬁes that the nearer alleles
that coexist on the same chromosome tend to be linked to each
other. The alleles that are far away from each other are more
likely to take place by chance, since the recombination events
between such alleles are more likely. The target of association
mapping is deﬁning alleles that raise the susceptibility to a dis-
ease. These alleles are more frequent among cases than among
controls. The SNP associated with a disease (risk or protective)
is an evidence for the association of its region with the disease.
So, the LD patterns are very useful for the identiﬁcation of
other indirect SNPs at the same region.
If two alleles that coexist on the same chromosome are
linked to each other, then a deviation (D) will be presented
in the observed frequencies from the expected frequencies.
(D) is one of the most common measures of LD [11]. Other
two valuable measures of LD are correlation coefﬁcient (r2)
and normalized deviation (D0). (r2) takes a value from zero
to one reﬂecting the strength of association between pairs of
alleles. Generally speaking, the strength of association between
SNPs decreases as the genetic distance between these SNPs
increases. The perfect LD quantitatively means (r2 = 1) [12].
The strong LD has a (r2) cut-off of 0.8 as generally seen in pub-
lished papers [13–15].
The recent sequencing/genotyping technologies allow com-
pletely sequencing large DNA segments or genotyping millions
of SNPs. However, the presence of LD between SNPs allows
reducing the number of genotyped SNPs and, therefore, reduc-
ing also the cost of the association study without a signiﬁcant
loss in the power of association [7].
Some studies on different genes of the human genome
showed that the structure of the human genome is blocky in
nature [16]. The observations of experiments concluded that
many chromosomes have blocky patterns [17]. The existence
of that blocky structure has a great advantage to the asso-
ciation studies. Haplotype blocks contain the structure of
LD in the human chromosomes. These blocks describe the
SNP pattern using a somewhat uncomplicated scheme. The
main properties of the haplotype block are: (a) the reduced
haplotype diversity within the block; (b) absence or very low
number of recombination events inside the block i.e. high
LD; (c) recombination events present between blocks i.e. low
LD [18]. Although recombination events are usually at the
boundaries of the haplotype blocks, a homogenous
recombination region will deceivingly look like a blocky pat-
tern of haplotypes. The relationship between any SNP in the
blocky pattern and all the other SNPs in the same pattern is
Fig. 2 The MHC region showing class I, class II, and class III
regions [39].
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block. A reduced set of tagging SNPs can be used to identify
all observed haplotypes instead of analyzing all SNPs within
the block [19].
Block extent varies greatly with different ethnicities.
Depending on this information, the US Nat’l Human Genome
Research Institute (USNHGRI) has started an extensive
endeavor, called the Int’l HapMap Project in 2002. This pro-
ject intended to construct a genome-wide map of LD and hap-
lotype blocks among populations. The sampled populations
were from European, Asian, and African ancestries. Four
countries provided the 270 DNA samples for HapMap project
which are US, Japan, China, and Nigeria. The US provided
samples of 30 trios (two parents and one adult child) from
Utah residents of European ancestry. Japan provided samples
of 45 unrelated residents from Tokyo area. Beijing, China pro-
vided 45 samples of unrelated Han Chinese. Nigeria provided
samples of 30 trios from the Yoruba people of Ibadan. The
number of genotyped SNPs is more than one million SNPs
with 5 kb (kilo base) inner intervals [20].
The 1000 Genomes Project was launched in 2008. The aim
of the project was to identify the genetic variants that have at
least 1% allele frequencies in the studied populations. The
studied populations were East Asians, South Asians, Africans,
Europeans, and Americans. Researchers could beneﬁt from
the identiﬁed variants by relating them to diseases through
association studies. Also, the project targeted the haplotype
background and LD patterns of the variant alleles [21].
The challenge of segmenting the genome into blocks of low
haplotype diversity is called haplotype block partitioning. The
main haplotype block partitioning methods are the four game-
te test (FGT) [22] and the conﬁdence interval test (CIT) [23].
There are other approaches to partition haplotype blocks such
as solid spine of LD [24], hidden markov model [25,26],
dynamic programming-based algorithm [27–29], wavelet
decomposition [30], greedy algorithm [31], minimum descrip-
tion length [32,33], and block entropy [34].
The target of haplotype block partitioning is to decrease the
complexity of association mapping so as to deal with haplo-
type blocks instead of individual SNPs. Other important appli-
cations of haplotype block partitioning are SNPs tagging,
post-GWAS SNP-set analysis, SNPs-to-gene mapping [35].
Haplotype blocks vs individual SNPs
Individual SNP approaches accomplished impressing ﬁndings
in case of monogenic diseases (such as cystic ﬁbrosis). On the
other hand, they did not reach the same success in complex dis-
eases (such as type I diabetes mellitus). Haplotype blocks may
capture interaction between SNPs (SNPs that contribute to the
disease status together but not separately), which is not possible
with individual-SNP tests [35]. Using individual SNP
approaches expands the dimension of association testing.
While using haplotype block methods reduces it with ensuring
reasonable error rates. So, the haplotype block methods are
expected to increase the power of association more than the
individual SNP approaches. The drawbacks of haplotype
blocks methods, (a) haplotype data are more expensive to col-
lect than genotype data; (b) phase (i.e. haplotype) estimation,
where the phase of SNPs can be homozygous or heterozygous;
(c) different haplotype block methods lead to different haplo-type blocks resulting in a problematic decision making in
choosing the best method for association mapping; (d) if the
number of haplotypes inside a block increases, the degree of
freedom of the block increases resulting in reduced power; (e)
applying statistical procedures ends up with computational
error. Some studies debated that individual SNPs will have at
least the same power of association as haplotype blocks.
Experimental results showed unclear conclusions in this debate.
The contradictory ﬁndings support that the performance of the
methods may depend on the nature of the studied data.
Shim et al. [36] aimed to measure the power of association
of the two strategies: the individual SNP approaches and the
haplotype block methods. They used a dataset from the North
American RA Consortium (NARAC) provided by the Genetic
Analysis Workshop 16 (GAW16). They tested 513,935 SNPs in
868 cases and 1194 controls. The examined haplotype block
methods were FGT and CIT implemented using Haploview
program. Haplotype block methods had lower p-values than
individual SNP approaches. A low p-value means that the
probability of observing these results by chance is very small.
Haplotype block methods reduced the no. of the required tests
using individual SNP approaches by a factor of about 0.65.
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ods only. This may be due to the higher ability of haplotype
block methods for detecting rare alleles. Other biomarkers
were detected by individual SNP approaches only. This may
be because of the neighboring SNPs, to the causal SNP in
the block, having weakened the strength of the association.
Finally, they suggested the use of the two strategies to maxi-
mize the detection of RA biomarkers.
RA biomarkers
The main biomarkers that have been considered as risk factors
for RA are within the major histocompatibility complex
(MHC) region which is positioned on chromosome 6
(6p21.3). The HLA region within the MHC contributes to
almost 50% of the genetic susceptibility for RA. Other RA
biomarkers outside the MHC region are also considered sig-
niﬁcant [37,38].
Biomarkers in the MHC region or chromosome 6
The MHC region is highly related to autoimmune diseases.
This relation has been shown through many association map-
ping studies. The MHC region extends over 3.6 Mb, as shown
in Fig. 2. The MHC region contains about 220 genes, many of
which have immunoregulatory functions [39].
HLA–DR4 and HLA–DRB1 genes are highly associated
with RA. The HLA–DRB1 associations are intensely detected
in the anti-CCP + (anti-cyclic citrullinated peptide positive)
antibodies group [40]. TNF locus is one of the most studied
loci in the MHC region. TNF locus is located inside the
MHC class III region, about 1000 kb from HLA–DRB1 [39].
HLA locus is associated with RA disease in multiethnic
populations. Muazzam et al. [41] conﬁrmed the haplotype
association of DRB1 and DQB1 variants of HLA class II with
RA in Pakistani population. Atouf et al. [42] veriﬁed that
HLA–DRB1*04 allele predisposed to RA, while HLA–
DRB1*07 allele had a protective role in Moroccan population.Fig. 3 LD structure for 12 SNPs at HLA–DRB1 and HLA–
DPB1. A constructed block was shown including eight SNPs, from
SNP 5 to SNP 12 [40].Al-Swailem et al. [43] provided that HLA–DRB1*04 prevailed
*08 and *10 alleles in association with RA, while DRB1*06
allele seemed protective to RA in Saudi Arabian population.
Ucar et al. [44] conﬁrmed the association of RA with HLA–
DRB1*01,*04, and *09 alleles, whereas *13 was the protective
allele against RA in Eastern Black Sea Turkish population.
Mourad and Monem [45] detected the association of Syrian
RA patients with HLA–DRB1*01, *04, and *10 alleles, while
*11 and *13 were the protective alleles against RA. Ben
Hamad et al. [46] indicated that HLA–DRB1*04, and *10 alle-
les are related with RA, while patients harboring DRB1*08
allele had a decreased risk of developing RA in the Southern
Tunisian population. HLA alleles had been veriﬁed in many
populations [47–63].
Ding et al. [40] identiﬁed other risk loci in the MHC region.
They studied RA patients in two risk groups, deﬁned accord-
ing to the presence or absence of ACPA. They reﬁned DRB1
common variants, and detected additional associations with
alleles near HLA–DPB1 for ACPA-positive RA patients, as
shown in Fig. 3. For ACPA-negative RA patients, they did
not ﬁnd any linkage with alleles within the MHC region.
Lee et al. [64] provided supplementary risk loci for RA in
the MHC region, separated from the class II HLA–DRB1
locus. This research suggested the existence of two regions of
association with RA in the class I region. HLA-C locus was
associated with RA (P  5 · 105). In addition, alleles located
near the ZNF311 (zinc ﬁnger protein 311) locus were detected.
A known risk variant at the TAGAP (T cell activation
RhoGTPase activating protein) gene locus represents a candi-
date, but not convincing, biomarker for association with RA
susceptibility. Chen et al. [65] reﬁned the TAGAP risk locus.
The SNP (rs212389) demonstrated a potent association with
RA disease (P = 3.9 · 108). This risk locus prevailed over-
whelmingly convincing upon the former RA SNP (rs394581,
P = 2.2 · 105).
NKAPL (NF-kB (nuclear factor kappa-light-chain-en-
hancer of activated B cells) activating protein-like) gene is
90% similar to NKAP gene. While NKAPL functions are still
unknown, NKAP is a protein implicated in NF-kB-mediated
transcriptional activation of TNF and IL-1 (interleukin 1
family). Xie et al. [66] ﬁne-mapped the NKAPL gene to verify
the association with RA disease. Fine-mapping analyses
detected six SNPs in a single haplotype block in CanadianFig. 4 Case-control association results at 6q23. The associated
SNP (rs10499194) was about 165 kb from both TNFAIP3 and
OLIG3 genes [67].
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(rs13208096) in the NKAPL gene showed the highest sig-
niﬁcance of association with RA susceptibility, and were repli-
cated in the US cohort. By illustrating supplementary NKAPL
alleles, the results conﬁrmed the potent association between
NKAPL and RA disease. These additional NKAPL variants
were associated with variants located in HLA–DRB1 locus.
NKAPL variants and HLA–DRB1 variants suggested a syner-
gistic effect between the two regions.
Plenge et al. [67] detected a SNP at 6q23 (rs10499194)
approximately 150 kb from (TNFAIP3 (TNF alpha-induced
protein 3), telomeric) and approximately 185 kb from (OLIG3
(oligodendrocyte transcription factor 3), centromeric), as
shown in Fig. 4. In a parallel research, the Wellcome Trust
Case Control Consortium (WTCCC) identiﬁed potent asso-
ciation of RA to a distinctive SNP (rs6920220) lied 3.8 kb from
(rs10499194).
TNFAIP3, which encodes protein A20, is a strong termina-
tor of the NF-kB signaling and is needed for inhibition of
TNF-induced signals. TNFa levels are elevated in RA patients.
Termination of TNFa is an effective treatment of severe RA.
In addition, mice showing shortage in TNFAIP3 present
chronic inﬂammation. TNFAIP3 plays a dominant role in
autoimmunity. There is a lack of information about OLIG3.
Mice, with mutation in OLIG3, have deﬁciencies in neuronal
development. But, abnormalities are not recognized in the
immune system or musculoskeletal system.
Biomarkers outside MHC region
Association mapping studies have led to the detection of genet-
ic biomarkers outside the MHC region. PTPN22 (protein tyr-
osine phosphatase non-receptor type 22) is identiﬁed as the
most statistically signiﬁcant biomarker for RA disease outside
the MHC region in populations of European ancestry.
TRAF1-C5 (TNF receptor-associated factor 1 – complement
component 5) region comes next PTPN22 in the signiﬁcance
of association with RA [68].PADI4 (peptidyl-arginine de-
iminases_type 4) appears to have important association with
RA in Asian populations. On the other hand, an association
between RA and PADI4 is not conﬁrmed in Caucasian
populations. These populations vary in environmental factors
which may explain the previous results [69].
Plenge et al. [70] tested 17 SNPs from 14 genes in 2370 RA
patients and 1757 controls from the NARAC and the Swedish
Epidemiological Investigation of RA (EIRA) datasets. All cas-
es and controls were of European descent. The association of
PTPN22 with ACPA-positive RA was conﬁrmed. Also, an
association with CTLA4 (cytotoxic T-lymphocyte antigen 4)
and PADI4 was provided, but in NARAC dataset only. The
results concluded that PTPN22 is associated with not only
RF-positive patients but also ACPA-positive patients. This
conclusion was expected, providing the vigorous correlation
between RF and CCP situation. Together, these ﬁndings gave
the most powerful indication of a non-MHC region that inﬂu-
enced the susceptibility to RA.
CD40 (cluster of differentiation 40) signaling plays a very
important role in innate and adaptive immunity against
microorganisms. CD40 is a member of the TNFR (TNF recep-
tor) family of genes and is expressed on B cells and antigen-p-
resenting myeloid cells. CD40 exists on chromosome region(20q13.1). Genetic studies on CD40 showed an association
with autoimmune diseases [71].
Raychaudhuri et al. [72] detected an allele at the CD40 gene
locus (rs4810485) which was susceptible for RA. This result
showed that CD40 was a critical player in RA pathogenesis.
They also detected another variant at the CCL21 (chemokine
(C–C motif) ligand 21) gene locus (rs2812378). CCL21 is a
gene involved in immunoregulatory functions. Finally, they
provided a proof of association at four supplementary gene
loci: MMEL1-TNFRSF14 (membrane metallo-endopepti-
dase-like 1 – TNFR superfamily member 14) (rs3890745),
CDK6 (cyclin-dependent protein kinase 6) (rs42041), PRKCQ
(protein kinase C theta type) (rs4750316), and KIF5A-
PIP4K2C (kinesin family member 5A-phosphatidylinositol-5-
phosphate 4-kinase, type II, gamma) (rs1678542).
Gregersen et al. [73] performed a GWAS for RA disease
patients from North America on a combined dataset of 2418
cases and 4504 controls. They provided an association at the
REL (reticuloendotheliosis) locus, which encodes protein c-
Rel, on chromosome region 2p13 (rs13031237, rs13017599).
The combined dataset also identiﬁed other variants at CTLA4
(rs231735) and BLK (B lymphocyte kinase) (rs2736340). c-Rel
has biological activity effects on hematopoietic cells, and is an
NF-kB family member. c-Rel was associated with RA provid-
ing disease tracks that included other known RA susceptibility
genes such as CD40, TRAF1, TNFAIP3 and PRKCQ.
Raychaudhuri et al. [74] tested 22 susceptibility loci in a
dataset of 7957 cases and 11,958 controls. Three loci were con-
clusively approved: (a) CD2–CD58 (cluster of differentiation
2-cluster of differentiation 58) (rs11586238); (b) CD28 (cluster
of differentiation 28) (rs1980422); and (c) PRDM1 (PR
domain zinc ﬁnger protein 1) (rs548234). A supplementary
four susceptibility genes were reproduced (P< 2.3 · 103):
TAGAP (rs394581), PTPRC (protein tyrosine phosphatase
receptor type C) (rs10919563), TRAF6–RAG1 (TRAF6-recom-
bination activating gene 1) (rs540386) and FCGR2A (Fc
fragment of IgG, low afﬁnity IIa) (rs12746613). Many of these
SNPs reveal some of the shared mechanism of RA patho-
genesis as they are also associated with other immunologic
diseases.
Kurreeman et al. [75] applied a research plan on distinct
populations to conﬁrm the identiﬁcation of universal RA risk
loci. Thirteen known risk variants were tested in different
sample sets consisting of overall 4366 cases and 17,765 controls
of European, African American, Japanese, and Korean
ethnicities. Two alleles (rs3890745 at the 1p36 locus) and
(rs2872507 at the 17q12 locus) overstepped genome-wide sig-
niﬁcance in all 16,659 RA cases and 49,174 controls combined.
They used GWAS data to reﬁne these two alleles in Europeans
and East Asians, and they conﬁrmed risk association in both
ethnic groups. A series of bioinformatics analyses identiﬁed
MMEL1–TNFRSF14 at the 1p36 locus and IKZF3-
ORMDL3-GSDMB (IKAROS family zinc ﬁnger 3-ORM1-like
3-gasdermin B) at the 17q12 locus as the genes most likely
associated with RA.
RA biomarkers in other diseases
RA and celiac disease (CD) show shared mechanism of disease
pathogenesis. They are two distinct autoimmune diseases with
co-occurrence in families. GWAS veriﬁed the HLA region and
Fig. 5 Manhattan plots of the GWAS meta-analysis for RA in
the Japanese population [80].
Rheumatoid arthritis biomarkers 726 non-HLA genetic variants in each disease. Past studies con-
ﬁrmed six SNPs occurring in both diseases out of the 26 risk
loci. Zhernakova et al. [76] thought to enhance the deﬁnition
of shared disease pathogenesis through identifying new risk
loci. They performed a combined analysis of 50,266 samples.
The study resulted in the identiﬁcation of new four SNPs that
were not previously veriﬁed in either disease: (a) the
rs10892279 near the DDX6 (DEAD (Asp-Glu-Ala-Asp) box
helicase 6), (b) the rs864537 near CD247 (cluster of differen-
tiation 247), (c) the rs2298428 near UBE2L3 (ubiquitin-conju-
gating enzyme E2L3), and (d) the rs11203203 near UBASH3A
(ubiquitin associated and SH3 domain containing A). Four
common variants associated in both diseases are conﬁrmed:
SH2B3 (SH2B adaptor protein 3), 8q24, STAT4, and
TRAF1-C5. These results involved genes responsible for
immune functions such as antigen presentation and T-cell
activation.
KCNB1 (potassium voltage-gated channel, shab-related
subfamily, member 1) is a candidate gene for association with
RA disease. This candidacy comes from the important func-
tion of KCNB1 in the immune system. Four identical KCNB1
sub-units are the main components of the functional channel
in human T lymphocytes. Autoimmune diseases such as type
1 diabetes mellitus and RA are medicated with several peptide
inhibitor of KCNB1. Noticeable defect in potassium channels
function involving KCNB1 by autoimmune diseases had been
conﬁrmed. Xiao et al. [77] examined the association between
KCNB1 and RA disease in GAW16 dataset. KCNB1 showed
moderate association with RA.
Chung et al. [78] tested common variants associated with
RA and GPA (granulomatosis with polyangiitis) (wegener’s).
They conducted a meta-analysis of GPA showing convincing
association with risk loci in CTLA4. The studied risk alleles
associated with RA were also signiﬁcantly associated with
GPA. RA and GPA may originate from a similar genetic
tendency.
Some genes are risk variants for several autoimmune dis-
eases. Li and Begovich [79] stated that the risk variant
TNFAIP3 was the only one that had been recorded in both
psoriasis and RA diseases. TNFAIP3 had also been associated
with SLE (systemic lupus erythematosus). These results
showed that RA, SLE, and psoriasis may originate from a
similar genetic predisposition. Also, TNFAIP3 was conﬁrmed
to play a complex role in different autoimmune diseases.
Okada et al. [80] conducted a GWAS for RA in a Japanese
cohort. They conﬁrmed strong association with RA disease at
nine loci. The nine variants were as follows:(1) B3GNT2 (UDP-GlcNAc: beta-1,3-N-acetylglu-
cosaminyltransferase 2),
(2) ANXA3 (annexin A3),
(3) CSF2 (colony stimulating factor 2),
(4) CD83 (cluster of differentiation 83),
(5) NFKBIE (NF-kB inhibitor, epsilon),
(6) ARID5B (AT rich interactive domain 5B),
(7) PDE2A-ARAP1 (phosphodiesterase 2A-ArfGAP with
RhoGAP domain, ankyrin repeat and PH domain 1),
(8) PLD4 (phospholipase D family, member 4) and
(9) PTPN2 (protein tyrosine phosphatase non-receptor type
2), as shown in Fig. 5.
ANXA3 gene, associated with RA, was also associated with
SLE. B3GNT2 and ARID5B were associated with suscepti-
bility to graves’ disease.
RA biomarkers in children
RA is an autoimmune disease, generally affects people during
middle age. Children with RF and/or ACPA-positive juvenile
idiopathic arthritis appear like adults with RA disease, and
represent the childhood onset of RA (CORA). Polymorphisms
within HLA and many other genes were evaluated for RA risk
susceptibility, but had not been investigated intensively in chil-
dren. To provide evidence that RA risk alleles would also be
connected to CORA, Prahalad et al. [81] examined RA SNPs
in large set of children with CORA. CORA was most frequent
among children of 11 years, and 85% of studied cases were
females. CORA and HLA–DRB1 SNPs revealed a signiﬁcant
association as the situation in RA disease. Genetic studies
showed a critical association between CORA and TNFAIP3,
PTPN22, and STAT4.
Ezzat et al. [82] studied the susceptibility of Egyptian chil-
dren to juvenile rheumatoid arthritis (JRA) associated with
HLA–DRB1 locus. They provided that HLA–DRB1*04 and
*14 prevailed DRB1*01 alleles in the association with JRA
in a study of 60 cases and 50 controls. HLA-DRB1*08 allele
seemed to be protective to JRA in Egyptian children.
Gender speciﬁc biomarkers
Caliz et al. [83] performed a study to analyze alleles in Th1 (T
helper 1 cells) and Th17 (T helper 17 cells) which are cell medi-
ated immune response genes. They aimed to investigate
whether the studied genes differently control RA susceptibility
in females and males. Patients accommodating Dectin-2 allele
(rs4264222T) had a critical RA susceptibility, while DC-SIGN
(dendritic cell-speciﬁc intercellular adhesion molecule-3-grab-
bing non-integrin) allele (rs4804803G), MCP-1 (monocyte
chemotactic protein-1) allele (rs1024611G), MCP-1 allele
(rs13900T) and MCP-1 allele (rs4586C) had a protective role
against RA.Dectin-2 allele (rs4264222T) and Dectin-2 allele
(rs7134303G) were associated with RA in females. MCP-1
alleles (rs1024611G), (rs13900T), and (rs4586C) increased the
immunization against RA in females. DC-SIGN allele
(rs2287886A) was associated with RA in males. DC-SIGN
allele (rs4804803G) played a protective role in RA in males.
They also concluded that Dectin-2 SNPs (rs4264222) and
(rs7134303) represented a potent two locus interaction model
Fig. 6 Manhattan plot of association with RA in the European
descents [87].
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SNPs. The last ﬁndings were not seen in men.
WTCCC detected a SNP (rs11761231), on chromosome 7q,
which presented gender relationship. This SNP showed a criti-
cal association with RA susceptibility only in females in a Bri-
tish population. Korman et al. [84] tested the same SNP in a
North American population but failed to ﬁnd any association
of the 7q region with RA.
Biomarkers in different populations
Stahl et al. [85] identiﬁed seven RA risk loci (P< 5 · 108) in
a study of all 41,282 samples from Canada, North America,
Sweden, Netherlands, UK, and US. The associated variants
were located close to genes of immunoregulatory functions,
involving the following:
(1) IL6ST (interleukin 6 signal transducer),
(2) SPRED2 (sprouty-related, EVH1 domain containing 2),
(3) RBPJ (recombination signal binding protein for immu-
noglobulin kappa J region),
(4) CCR6 (chemokine (C–C motif) receptor 6),
(5) IRF5 (interferon regulatory factor 5),
(6) C5orf30 (chromosome 5 open reading frame 30), and
(7) PXK (PX domain containing serine/threonine kinase).
They also enhanced associations at two RA common vari-
ants (IL2RA (interleukin 2 receptor, alpha) and CCL21) and
veriﬁed the association at AFF3 (AF4/FMR2 family, member
3).
Hughes et al. [86] tested whether the validated RA SNPs
among people of European ancestry are linked to RA risk loci
in an African American population. Twenty-four of the 27
examined SNPs had been conﬁrmed for the association with
RA in the European and African American populations. On
the contrary, the remaining 3 of the 27 SNPs (CCR6, TAGAP,
and TNFAIP3 (rs6920220)) failed to represent acceptable asso-
ciation with RA in African American population.Eyre et al. [87] tested 14 alleles, 5 of which were deﬁnitely
associated with ACPA-positive RA patients and, 9 of which
were associated generally with RA disease. The studied popula-
tions were from Canada, North America, Sweden, Spain,
Netherlands, UK, and US. The genes involved in RA suscepti-
bility in European descents in that study were shown in Fig. 6.
Many of the identiﬁed biomarkers of RA belong to Cau-
casian populations. Viatte et al. [88] examined the association
of Caucasian non-HLA alleles with RA patients in Black Afri-
can populations. They found weak association between most
of the SNPs and West/Central African population. RA suscep-
tibility SNPs, grouped in a set of 28 Caucasian alleles, were
highly distinct between the UK and Africa with (p< 0.001).
They concluded that the genetic risk variants of developing
RA are different in Africans from Caucasians. Interestingly,
these results conﬁrmed that ethnic group had a great inﬂuence
on the genetic architecture of RA susceptibility, forcing the
researchers to identify the RA SNPs of each ethnic group
separately.
Weak association between PADI4 and RA susceptibility
was noticed in Caucasian cohorts. PADI4 was convincingly
associated with RA disease in East Asian populations. Too
et al. [89] aimed to verify the association between PADI4
and RA susceptibility in Malaysian, Chinese, Indians, and
other populations from South East Asia. The results presented
that PADI4 and RA were associated in the multiethnic popula-
tions from South East Asia and provided supplementary asso-
ciation with PADI2 risk locus. PADI2 and PADI4 genes
contributed to enzymes responsible for citrullination. The
results thus veriﬁed the association of RA with PADI4 in mul-
tiple populations of Asian descent.
The MTHFR (Methylenetetrahydrofolate reductase) is a
catalytic enzyme which plays an essential role in the conversion
of 5,10-methylenetetra-hydrofolate to 5-methyltetrahydrofo-
late. 5-methyltetrahydrofolate helps in the conversion of
methionine from homocystine in vitamin B12 dependent path-
way. Homocysteine was recorded at high levels in RA patients.
In further reactions, methionine is converted to S-adenosylme-
thionine. S-adenosylmethionine helps in nucleotide methyla-
tion in DNA, RNA, and proteins. The MTHFR gene is
located on 1p36 region. The A1298C is a common polymor-
phism in the MTHFR gene. The A1298C was veriﬁed as a
biomarker for RA disease in Jewish and Italian populations
[90,91]. Contradictory results were shown in American popula-
tion with Caucasian and African ethnicities [92]. The allele
(1298C) was found to exhibit lower MTHFR enzyme activity,
hyperhomocysteinemia, and decreased folate levels.
Okada et al. [93] conducted a GWAS for RA in 29,880 cases
and 73,758 controls of European and Asian ancestries. The
total number of studied SNPs was nearly 10 million. They iden-
tiﬁed 42 novel risk loci for association with RA. The results of
the study led to the expansion of the detected RA risk loci to
101. They also designed a systematic strategy to identify 98 bio-
logical candidate genes at these 101 risk loci. These genes should
be targeted for RA drug discovery and further repurpose
approved drugs for other diseases for RA treatment.
Haplotype blocks in RA biomarker discovery
Suzuki et al. [94] tested a haplotype block, consisted of 17
SNPs, for association with RA in PADI4 gene. Expectation
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were expected to have a frequency of more than 0.02 in both
patient and healthy individual groups. Four haplotypes, out
of 217 possible haplotypes, fulﬁlled the condition. The most
redundant haplotype (haplotype 1) and the second most
redundant haplotype (haplotype 2) together represented more
than 85% of the observed haplotypes in both groups. Haplo-
type 1 was mainly detected in healthy individuals and was
called the non-susceptible haplotype. Haplotype 2 was mainly
detected in patients and was called the susceptible haplotype.
Next, they aimed to test the haplotypes affecting the stability
of PADI4 mRNA. They concluded that susceptible mRNA
had higher stability than non-susceptible mRNA. Further-
more, the susceptible haplotype was associated with higher
levels of antibody to citrullinated peptide in patients’ sera.
Ikari et al. [95] tested a haplotype block within PTPN22
gene, consisted of 8 SNPs spanning 45 kb, for association with
RA in Japanese population. Expectation maximization
method was used to detect the haplotypes that were expected
to have a frequency of more than 0.01 in the studied groups.
Finally, they did not detect any association with RA in Japane-
se population.
Plenge et al. [96] tested a haplotype block in PHF19 (PHD
ﬁnger protein 19)-TRAF1-C5 region, containing nine tag SNPs
extends for 100 kb, for association with RA in NARAC II and
EIRA II. Omnibus association test was used to test all haplo-
types combined for association with RA. The SNP(rs3761847)
was identiﬁed as a susceptible SNP for RA and veriﬁed using
logestic regression analyses. Another SNP (rs2900180) was
also identiﬁed as a susceptible SNP for RA. These two SNPs
were in strong LD with each other (r2 = 0.62). So, the causal
ungenotyped variant was considered to be in strong LD with
these two polymorphisms. Interestingly, they detected a syn-
onymous SNP in TRAF1 gene (rs2239657) which demonstrat-
ed near perfect LD (r2 = 0.97) with (rs2900180).
The detected SNP (rs4810485) in [72] was located in a hap-
lotype block containing about the entire CD40 gene. The
SNP(rs1883832) which had been associated with graves’ dis-
ease, was in a very strong LD (r2 = 0.95) with (rs4810485).
Another detected SNP (rs2812378) was located in a haplotype
block containing the entire CCL21 gene.
Plenge et al. [67] tested a haplotype block in 6q23 region,
with 20 SNPs extended for 63 kb, for association with RA cas-
es from the Brigham RA Sequential Study (BRASS) and con-
trols from Framingham Heart Study (FHS). Logestic
regression analyses and omnibus association test were used
to test all haplotypes for association with RA. Six different
haplotypes, with ﬁve tag SNPs, represented 96% of the total
haplotypes with a frequency of more than 0.05. The
SNP(rs6920220) was identiﬁed as a susceptible SNP for RA,
while SNP(rs10499194) showed a protective role against RA.
Scherer et al. [97] used the haplotype block, deﬁned in [67],
for detecting the linkage between 6q23 region and the rate of
joint destruction in early RA Dutch patients. The
SNPs(rs675520G) and (rs9376293C) were identiﬁed as two sus-
ceptible alleles for increased joint destruction in ACPA-posi-
tive patients.
Zhang et al. [98] promoted a GWAS based on haplotypes,
extended for 1 Mb, to search for risk loci and associated genes
for RA. The dataset consisted of 5,393 informative SNPs con-
taining 822 uncorrelated individuals which were obtained from
NARAC. They used FGT, CIT, solid spine of LD, and fusionof these methods to identify the haplotype blocks. Density-
based clustering algorithm was used to select the ﬁnal set of
risk haplotypes based on the Pearson correlation coefﬁcient
for the nearest neighbor method. They detected 25 haplotypes
in 18 haplotype blocks. These haplotype blocks contained 33
genes which are highly associated with the risk of RA. The
genes PTPRC and F12 (coagulation factor 12) prevailed the
other genes in RA susceptibility.
Xie et al. [66] tested three haplotype blocks in NKAPL
region, consisted of 101 SNPs within 372 kb, for association
with RA in Canadian patients. They used the CIT method to
identify the haplotype blocks. Benjamini and Hochberg’s false
discovery rate method showed that there were six statistically
signiﬁcant SNPs associated with RA. These SNPs were all
located in the middle haplotype block, across about 70 kb
region, which contained NKAPL, ZNF193, ZNF307, and
ZNF187 genes. ZNF193 (rs35656932) and NKAPL
(rs13208096) were identiﬁed as the highest two susceptible
SNPs for RA. This result was veriﬁed using stepwise and con-
ditional logestic regression analyses.
SE represented a strong association with ACPA-positive
RA patients. SE encoded consensus amino acid sequences
extended from 70 to 74 positions in HLA-DRB1. Raychaud-
huri et al. [99] tried to fully explain the association with RA
within MHC region in addition to SE. They tested 99 classical
HLA alleles at two-digit resolution, 164 classical HLA alleles
at four-digit resolution, 372 polymorphic amino acid positions,
and 3,117 SNPs for association with ACPA-positive RA in
BRASS, EIRA, NARAC I, NARAC III, WTCCC, and Cana-
dian datasets using logistic regression. Conditional haplotype
analyses uncovered new ﬁndings within the MHC region.
HLA-DRB1 codon 11, rs17878703A (a quadrallelic SNP),
was identiﬁed as the highest susceptible SNP for RA. SNPs
at codon 13 were in strong LD (r2 not speciﬁed) with those
of codon 11 resulting in a double inﬂuence at this region. These
ﬁndings were veriﬁed in a South Korean dataset. The two SE
positions, 71 and 74, came after the position 11 in association
with RA. Furthermore, HLA-B codon 9 and HLA-DPB1
codon 9 were also associated with RA within the MHC region.
Park et al. [100] explored the interaction among haplotypes
through two steps. At the ﬁrst step, they tested the whole gen-
ome by individual-SNP methods (codominant and additive
models). Then, the haplotype blocks of the signiﬁcant SNPs
were identiﬁed. They used the CIT method to identify the hap-
lotype blocks. At the second step, the interactions among hap-
lotypes were detected using expectation maximization method
and contingency table. The individual-SNP methods followed
by the haplotype block method detected 411 signiﬁcant SNPs
and 146 haplotype blocks. Some previous detected genes that
associated with RA were conﬁrmed such as PTPN22, TRAF1,
NFKBIL1, HLA-C, and HLA-G. Two non-synonymous SNPs
showed shared mechanism of disease pathogenesis. The
SNP(rs2075800) in HSPA1L (Heat Shock 70 kDa Protein 1-
Like) was associated with both RA and sarcoidosis. The
SNP(rs2476601) in PTPN22 was associated with type I dia-
betes mellitus, RA, SLE, and hashimoto thyroiditis.
Most of GWAS ﬁndings in RA are because of common
SNPs that do not affect protein coding regions. Diogo et al.
[101] identiﬁed SNPs in three genes that encode proteins that
involved in RA immunopathogenesis. The three genes were
IL2RA, IL2RB, and CD2. Then, they tried to verify the
association of CD2 with RA susceptibility using conditional
Table 1 Detected SNPs associated with RA succeptibility.
SNP Gene Position Method Population Comment Reference
rs3117213 HLA-DPB1 33,172,583 Individual-SNP EIRA, NARAC ACPA + [40]
rs6923005 ZNF311 29,084,051 Individual-SNP NARAC, Wichita
Rheumatic Disease Data
Bank (WRDDB), the
National Inception
Cohort of RA Patients
(NICRAP), Study of
New Onset RA
(SONORA)
ACPA + [64]
rs6930903 29,089,224 Individual-SNP
rs212389 TAGAP 159,068,759 Individual-SNP BRASS, Canada, EIRA,
NARAC I, NARAC III,
WTCCC
ACPA+ or RF + [65]
rs2476601 PTPN22 113,834,946 Individual-SNP EIRA, NARAC [70]
rs2240340 PADI4 17,336,144 Individual-SNP NARAC
rs3087243 CTLA4 203,874,196 Individual-SNP NARAC
rs4810485 CD40 44,181,354 Individual-SNP EIRA, NARAC,
WTCCC, Nurses Health
Study (NHS), BRASS,
NARAC II, NARAC
III, Genomics
Collaborative Initiative
(GCI), Leiden
University Medical
Center (LUMC), EIRA-
II, Genetics Network
Rheumatology
Amsterdam (GENRA)
100% (ACPA+ or RF+),
except for WTCCC (80%
ACPA+, 84% RF+)
[72]
rs1883832 CD40 46,118,343 LD
rs2812378 CCL21 34,700,260 Individual-SNP
rs3890745 MMEL1-TNFRSF14 2,585,786 Individual-SNP
rs42041 CDK6 91,891,395 Individual-SNP
rs4750316 PRKCQ 6,433,266 Individual-SNP
rs1678542 KIF5A-PIP4K2C 56,254,982 Individual-SNP
rs13031237 REL 60,908,994 Individual-SNP Canada and USA
(European descent)
95% ACPA+ [73]
rs13017599 60,937,196 Individual-SNP
rs231735 CTLA4 203,829,153 Individual-SNP
rs2736340 BLK 11,486,464 Individual-SNP
rs11586238 CD2-CD58 116,720,516 Individual-SNP Using GRAIL (Gene
Relationships Across
Implicated Loci)
[74]
rs1980422 CD28 203,745,673 Individual-SNP
rs548234 PRDM1 106,120,159 Individual-SNP
rs394581 TAGAP 159,061,489 Individual-SNP
rs10919563 PTPRC 198,731,313 Individual-SNP
rs540386 TRAF6-RAG1 36,503,743 Individual-SNP
rs12746613 FCGR2A 161,497,252 Individual-SNP
rs3890745 MMEL1-TNFRSF14 2,585,786 Individual-SNP European, African
American, Japanese, and
Korean ethnicities
[75]
rs2872507 IKZF3-ORMDL3-GSDMB 39,884,510 Individual-SNP
rs10892279 DDX6 118,741,072 Individual-SNP GWAS Meta-Analysis [76]
rs864537 CD247 167,442,147 Individual-SNP
rs2298428 UBE2L3 21,628,603 Individual-SNP
rs11203203 UBASH3A 42,416,077 Individual-SNP
rs653178 SH2B3 111,569,952 Individual-SNP
rs975730 8q24.2 128,303,768 Individual-SNP
rs1953126 TRAF1 120,878,222 Individual-SNP
rs7574865 STAT4 191,099,907 Individual-SNP
rs1051295 KCNB1 49,372,368 Individual-SNP NARAC [77]
rs3087243 CTLA4 203,874,196 Individual-SNP European Descent GPA [78]
rs11900673 B3GNT2 62,225,526 Individual-SNP Japanese 81.4% ACPA+, 80.4% RF+ [80]
rs2867461 ANXA3 78,592,061 Individual-SNP
rs657075 CSF2 132,094,425 Individual-SNP
rs12529514 CD83 14,096,427 Individual-SNP
rs2233434 NFKBIE 44,265,183 Individual-SNP
rs10821944 ARID5B 62,025,330 Individual-SNP
rs3781913 PDE2A-ARAP1 72,662,452 Individual-SNP
rs2841277 PLD4 104,924,668 Individual-SNP
rs2847297 PTPN2 12,797,695 Individual-SNP
(continued on next page)
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Table 1 (continued)
SNP Gene Position Method Population Comment Reference
rs2476601 PTPN22 113,834,946 Individual-SNP Non-hispanic white
children
ACPA+ or RF+ [81]
rs7574865 STAT4 191,099,907 Individual-SNP
rs10499194 TNFAIP3 137,681,500 Individual-SNP
rs4264222 Dectin-2 8,459,172 Individual-SNP Caucasian (Spain and
Portugal)
[83]
rs4804803 DC-SIGN 7,747,847 Individual-SNP
rs1024611 MCP-1 34,252,769 Individual-SNP
rs13900 34,256,892 Individual-SNP
rs4586 34,256,250 Individual-SNP
rs6859219 IL6ST 56,142,753 Individual-SNP BRASS, CANADA,
EIRA, NARAC I,
NARAC III, WTCCC,
CANADA II, Dutch,
GENRA, GCI, LUMC,
NARAC II, United
Kingdom RA Genetics
(UKRAG), and NHS
ACPA+ or RF+ [85]
rs934734 SPRED2 65,368,452 Individual-SNP
rs26232 C5orf30 103,261,019 Individual-SNP
rs874040 RBPJ 26,106,575 Individual-SNP
rs3093023 CCR6 167,120,802 Individual-SNP
rs10488631 IRF5 128,954,129 Individual-SNP
rs13315591 PXK 58,571,114 Individual-SNP
rs706778 IL2RA 6,056,986 Individual-SNP
rs951005 CCL21 34,743,684 Individual-SNP
rs11676922 AFF3 100,190,478 Individual-SNP
rs34536443 TYK2 10,352,442 Individual-SNP UK, EIRA, US, Dutch,
Swedish Umea, Spanish,
BRASS, CANADA,
NARAC II, and
WTCCC
[87]
rs13397 IRAK1 153,982,797 Individual-SNP
rs8026898 TLE3 69,699,078 Individual-SNP
rs8043085 RASGRP1 38,535,939 Individual-SNP
rs2240336 PADI4 17,347,907 Individual-SNP
rs2228145 IL6R 154,454,494 Individual-SNP
rs13330176 IRF8 85,985,481 Individual-SNP
rs12764378 ARID5B 62,040,245 Individual-SNP
rs9979383 RUNX1 35,343,463 Individual-SNP
rs12936409 IKZF3 39,887,396 Individual-SNP
rs2872507 39,884,510 Individual-SNP
rs883220 POU3F1 38,151,199 Individual-SNP
rs2834512 RCAN1 34,539,301 Individual-SNP
rs595158 CD5 61,142,109 Individual-SNP
rs2275806 GATA3 8,053,377 Individual-SNP
rs2240340 PADI4 17,336,144 Individual-SNP Malaysian
Epidemiological
Investigation of RA
(MyEIRA)
[89]
rs1005753 PADI2 17,118,274 Individual-SNP
rs1801131 MTHFR 11,854,476 Individual-SNP Jewish and north Italians [90,91]
rs699738 CD2 116,768,525 Haplotype Block UK, EIRA, US, Dutch,
Swedish Umea, Spanish,
BRASS, CANADA,
NARAC II, and
WTCCC
ACPA + [101]
rs624988 116,721,168
rs798036 116,766,208
rs11203366 PADI4 17,331,039 Haplotype Block Japanese 75% RF+ [94]
rs11203367 17,331,121
rs874881 17,334,004
rs1748033 17,336,167
rs17878703 HLA–DRB1 32,584,360 Haplotype Block BRASS, CANADA,
EIRA, NARAC I,
NARAC III, WTCCC
ACPA+ [99]
rs13195291 ZNF193 28,201,463 Haplotype Block Canada, USA
(European Ancestry)
[66]
rs35656932 28,223,510
rs13204012 28,233,753
rs17720293 ZNF307 28,246,920
rs13208096 NKAPL 28,257,533
rs67998226 ZNF187 28,270,281
rs6920220 TNFAIP3-OLIG3 137,685,367 Haplotype Block BRASS, FHS, NARAC
I, EIRA
ACPA + [67]
rs10499194 137,681,500
rs3761847 TRAF1 120,927,961 Haplotype Block NARAC I, NARAC II,
EIRA I, EIRA II
ACPA + [96]
rs2900180 TRAF1-C5 120,944,104
rs2239657 TRAF1 120,909,242 LD
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Table 2 Studies that agree/disagree with other studies.
Gene Conﬁrmed in Not detected in References
CTLA4 North Americans, European and Asian ancestries Swedish [70,73,93]
TAGAP European ancestry African Americans [65,74,86]
FCGR2A Europeans Taiwanese, Europeans or Asians [74,102,103]
MMEL1-TNFRSF14 European ancestry – [72,75]
TRAF1 European ancestry – [76,104]
STAT4 European ancestry – [76,105]
PADI4 North Americans and Asians Swedish [70,89,94]
7q British females North Americans [84,106]
CCR6 Europeans African Americans [85,86]
TNFAIP3
MTHFR Jewish and Italians Americans (Africans and Caucasians) [90–92]
12 M.N. Saad et al.haplotype analysis. They detected missense SNPs (rs798036,
rs699738) and a noncoding SNP (rs624988) in CD2 which
had the best signal of association in the conditional haplotype
analysis.
IL2R consists of IL2Ra (encoded by IL2RA), IL2Rb
(encoded by IL2RB), and the common gamma chain
(CD132). The holding down of IL2Ra or IL2Rb in mice leads
to destructive autoimmunity. CD2 encodes CD2 protein which
is a cell-surface antigen located on T cells. The activation of
regulatory T cells (through CD4+ and IL2Ra+) coactivates
CD2 leading to the suppression of T cells. The regulatory T
cells deal with proinﬂammatory processes. The regulatory T
cells are functionally compromised in RA patients.
Table 1 summarized the detected SNPs associated with RA.
Table 1 showed the SNP ID, the related gene, the SNP posi-
tion in the genome, the used method for identiﬁcation, and
the studied population. The used methods for the detection
of the associated SNPs were individual-SNP methods, LD,
and haplotype block methods.
Studies that agree/disagree with others
This section shows the studies which agree/disagree with
others. The study, carried out by Gregersen et al. [73], was
in line with that conducted by Plenge et al. [70] verifying the
association of CTLA4 with RA in North Americans. But the
study carried out by Plenge et al. [70] did not detect the asso-
ciation of CTLA4 with RA in Swedish population, while the
study carried out by Okada et al. [93] conﬁrmed the asso-
ciation of CTLA4 with RA in European and Asian ancestries.
The study, conducted by Chen et al. [65], supported the results
obtained by Raychaudhuri et al. [74] for the association of
TAGAP with RA susceptibility in European ancestry. Howev-
er, TAGAP did not show any association with RA in African
Americans through Hughes et al. [86] study. The results,
obtained by Raychaudhuri et al. [74], contradicted the ﬁndings
of Chen et al. [102] for the association of FCGR2A with RA.
This contradiction might be due to the different population
ancestries (Europeans and Taiwanese) in the two studies. Also,
the very small sample size used in Chen et al. study [102] com-
pared with that in Raychaudhuri et al. study [74] might be the
reason. Controversially, the ﬁndings of Lee et al. [103]
supported the ﬁndings of Chen et al. [102] for the lack of asso-
ciation of FCGR2A with RA in Europeans or Asians.The study, conducted by Kurreeman et al. [75], agreed with
the study carried out by Raychaudhuri et al. [72] for the asso-
ciation of MMEL1-TNFRSF14 with RA in European ances-
try. The ﬁndings of Raychaudhuri et al. [72] and Okada
et al. [80] supported that RA and graves’ disease might have
a shared mechanism of disease pathogenesis (B3GNT2
(rs11900673), ARID5B (rs10821944), and CD40 (rs1883832)).
The study, carried out by Zhernakova et al. [76], conﬁrmed
the results of Han et al. [104] for the association of TRAF1
with RA in European ancestry. The ﬁndings of both studies
(Daha et al. [105] and Zhernakova et al. [76]) conﬁrmed the
association of STAT4 with RA in European ancestry.
The MTHFR was conﬁrmed for association with RA sus-
ceptibility in Jewish and Italian populations [90,91]. However,
the study conducted by Hughes et al. [92] showed contradicto-
ry results in American Africans and Caucasians. The negative
ﬁndings found in the Americans might be due to the enrich-
ment of the ﬂour products in the US with folic acid since
1998 [91]. The PADI4 was conﬁrmed as an RA biomarker in
the Asian populations through Too et al. [89] and Suzuki
et al. [94] studies. Also, Plenge et al. [70] detected the asso-
ciation of PADI4 with RA in North Americans but not in
Swedish population. The 7q region showed contradictory
results for association with RA in British (females) and North
American populations. These ﬁndings were found in studies
performed by the WTCCC [106] and Korman et al. [84] respec-
tively. The study, conducted by Hughes et al. [86], was not in
line with the study of Stahl et al. [85] for the association of
CCR6 and TNFAIP3 with RA in African Americans and
Europeans respectively.
Table 2, summarizing the above ﬁndings, showed the stud-
ies that conﬁrm/contradict one another in the association of
certain genes with RA in different ethnicities. RA biomarkers
have been increased through the last decade and still increas-
ing. To conclude, the journey to uncover all RA biomarkers
seems to be endless unless large scale trans-ethnic studies take
place.
Conclusions
RA is an autoimmune disease that is considerably spread all
over the world. Researchers believe that RA has genetic and
environmental causes for attacking the body joints. SNPs play
a vital role in shedding the light on genes and biological
Rheumatoid arthritis biomarkers 13pathways that contribute to RA. Reviewing the literature,
HLA-DRB1 seems to be the most successful candidate for
the title of RA universal biomarker depending on the large
number of studies providing its association with RA patients
worldwide, and even with JRA.
Most of the applied strategies on the discovery of RA
biomarkers are the individual SNP approaches. Later on, the
LD mapping techniques are used to detect the correlation
among the studied SNP and the neighboring SNPs to identify
the causal SNPs. Recently, GWAS have facilitated the empiri-
cal study of large dataset of SNPs. Then, the haplotype block
methods were introduced to detect the association of RA with
a whole block instead of a SNP.
Future work should concentrate on the unstudied
populations, comparison among different populations, RF
and CCP status, disease severity, gender related genes,
JRA biomarkers, disease outcomes, response to therapies,
and shared mechanism of disease pathogenesis. Extensive
work in these areas should lead to understanding the eti-
ology of RA, identiﬁcation of further biological pathways,
new RA drug discovery, and personal treatment of RA
patients.
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